Telemedicine for Follow-up Management of Patients After Liver Transplantation: Cohort Study.

cohort health-related quality of life liver transplantation morbidity mortality optimal clinical outcomes rapid recovery remote health monitoring telehealth telemedical follow-up management system telemedicine telerobotics

Journal

JMIR medical informatics
ISSN: 2291-9694
Titre abrégé: JMIR Med Inform
Pays: Canada
ID NLM: 101645109

Informations de publication

Date de publication:
17 May 2021
Historique:
received: 17 01 2021
accepted: 15 04 2021
revised: 11 04 2021
entrez: 17 5 2021
pubmed: 18 5 2021
medline: 18 5 2021
Statut: epublish

Résumé

Technical capabilities for performing liver transplantation have developed rapidly; however, the lack of available livers has prompted the utilization of edge donor grafts, including those donated after circulatory death, older donors, and hepatic steatosis, thereby rendering it difficult to define optimal clinical outcomes. We aimed to investigate the efficacy of telemedicine for follow-up management after liver transplantation. To determine the efficacy of telemedicine for follow-up after liver transplantation, we performed a clinical observation cohort study to evaluate the rate of recovery, readmission rate within 30 days after discharge, mortality, and morbidity. Patients (n=110) who underwent liver transplantation (with livers from organ donation after citizen's death) were randomly assigned to receive either telemedicine-based follow-up management for 2 weeks in addition to the usual care or usual care follow-up only. Patients in the telemedicine group were given a robot free-of-charge for 2 weeks of follow-up. Using the robot, patients interacted daily, for approximately 20 minutes, with transplant specialists who assessed respiratory rate, electrocardiogram, blood pressure, oxygen saturation, and blood glucose level; asked patients about immunosuppressant medication use, diet, sleep, gastrointestinal function, exercise, and T-tube drainage; and recommended rehabilitation exercises. No differences were detected between patients in the telemedicine group (n=52) and those in the usual care group (n=50) regarding age (P=.17), the model for end-stage liver disease score (MELD, P=.14), operation time (P=.51), blood loss (P=.07), and transfusion volume (P=.13). The length and expenses of the initial hospitalization (P=.03 and P=.049) were lower in the telemedicine group than they were in the usual care follow-up group. The number of patients with MELD score ≥30 before liver transplantation was greater in the usual care follow-up group than that in the telemedicine group. Furthermore, the readmission rate within 30 days after discharge was markedly lower in the telemedicine group than in the usual care follow-up group (P=.02). The postoperative survival rates at 12 months in the telemedicine group and the usual care follow-up group were 94.2% and 90.0% (P=.65), respectively. Warning signs of complications were detected early and treated in time in the telemedicine group. Furthermore, no significant difference was detected in the long-term visit cumulative survival rate between the two groups (P=.50). Rapid recovery and markedly lower readmission rates within 30 days after discharge were evident for telemedicine follow-up management of patients post-liver transplantation, which might be due to high-efficiency in perioperative and follow-up management. Moreover, telemedicine follow-up management promotes the self-management and medication adherence, which improves patients' health-related quality of life and facilitates achieving optimal clinical outcomes in post-liver transplantation.

Sections du résumé

BACKGROUND BACKGROUND
Technical capabilities for performing liver transplantation have developed rapidly; however, the lack of available livers has prompted the utilization of edge donor grafts, including those donated after circulatory death, older donors, and hepatic steatosis, thereby rendering it difficult to define optimal clinical outcomes.
OBJECTIVE OBJECTIVE
We aimed to investigate the efficacy of telemedicine for follow-up management after liver transplantation.
METHODS METHODS
To determine the efficacy of telemedicine for follow-up after liver transplantation, we performed a clinical observation cohort study to evaluate the rate of recovery, readmission rate within 30 days after discharge, mortality, and morbidity. Patients (n=110) who underwent liver transplantation (with livers from organ donation after citizen's death) were randomly assigned to receive either telemedicine-based follow-up management for 2 weeks in addition to the usual care or usual care follow-up only. Patients in the telemedicine group were given a robot free-of-charge for 2 weeks of follow-up. Using the robot, patients interacted daily, for approximately 20 minutes, with transplant specialists who assessed respiratory rate, electrocardiogram, blood pressure, oxygen saturation, and blood glucose level; asked patients about immunosuppressant medication use, diet, sleep, gastrointestinal function, exercise, and T-tube drainage; and recommended rehabilitation exercises.
RESULTS RESULTS
No differences were detected between patients in the telemedicine group (n=52) and those in the usual care group (n=50) regarding age (P=.17), the model for end-stage liver disease score (MELD, P=.14), operation time (P=.51), blood loss (P=.07), and transfusion volume (P=.13). The length and expenses of the initial hospitalization (P=.03 and P=.049) were lower in the telemedicine group than they were in the usual care follow-up group. The number of patients with MELD score ≥30 before liver transplantation was greater in the usual care follow-up group than that in the telemedicine group. Furthermore, the readmission rate within 30 days after discharge was markedly lower in the telemedicine group than in the usual care follow-up group (P=.02). The postoperative survival rates at 12 months in the telemedicine group and the usual care follow-up group were 94.2% and 90.0% (P=.65), respectively. Warning signs of complications were detected early and treated in time in the telemedicine group. Furthermore, no significant difference was detected in the long-term visit cumulative survival rate between the two groups (P=.50).
CONCLUSIONS CONCLUSIONS
Rapid recovery and markedly lower readmission rates within 30 days after discharge were evident for telemedicine follow-up management of patients post-liver transplantation, which might be due to high-efficiency in perioperative and follow-up management. Moreover, telemedicine follow-up management promotes the self-management and medication adherence, which improves patients' health-related quality of life and facilitates achieving optimal clinical outcomes in post-liver transplantation.

Identifiants

pubmed: 33999008
pii: v9i5e27175
doi: 10.2196/27175
pmc: PMC8167618
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e27175

Informations de copyright

©Min Tian, Bo Wang, Zhao Xue, Dinghui Dong, Xuemin Liu, Rongqian Wu, Liang Yu, Junxi Xiang, Xiaogang Zhang, Xufeng Zhang, Yi Lv. Originally published in JMIR Medical Informatics (https://medinform.jmir.org), 17.05.2021.

Références

Eur Respir J. 2012 Jun;39(6):1313-8
pubmed: 22075488
Hepatology. 2014 Dec;60(6):2099-108
pubmed: 25164003
N Engl J Med. 1989 Oct 12;321(15):1014-22
pubmed: 2674716
Eur Heart J. 2016 Jan 1;37(1):63-6
pubmed: 26303835
Surgery. 2017 Sep;162(3):525-536
pubmed: 28624178
Ann Intern Med. 2015 Nov 17;163(10):787-9
pubmed: 26344925
PLoS One. 2019 Jul 31;14(7):e0220527
pubmed: 31365594
Gastroenterology. 2015 Feb;148(2):307-23
pubmed: 25224524
J Zhejiang Univ Sci B. 2018 Jul;19(7):497-504
pubmed: 29971988
J Med Internet Res. 2010 Dec 15;12(4):e66
pubmed: 21159599
Medicine (Baltimore). 2016 Aug;95(31):e4198
pubmed: 27495023
Liver Transpl. 2017 Oct;23(10):1328-1341
pubmed: 28741309
Breathe (Sheff). 2016 Dec;12(4):350-356
pubmed: 28210321
Intern Emerg Med. 2020 Oct;15(7):1275-1279
pubmed: 32248403
Eur Respir J. 2011 Feb;37(2):310-7
pubmed: 20562122
Ann Surg. 2019 Aug;270(2):333-339
pubmed: 29958229
J Hepatol. 2019 May;70(5):855-865
pubmed: 30639505
Ann Surg. 2013 Sep;258(3):409-21
pubmed: 24022434
Lancet. 2018 Sep 22;392(10152):1047-1057
pubmed: 30153985
J Vasc Interv Radiol. 1995 Jul-Aug;6(4):523-9
pubmed: 7579858
Eur J Surg Oncol. 2013 Feb;39(2):156-63
pubmed: 23102705
Liver Transpl. 2020 May;26(5):702-708
pubmed: 32128971
World J Transplant. 2019 Jan 16;9(1):14-20
pubmed: 30697517
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2015 Oct;58(10):1056-61
pubmed: 26281718
Ther Adv Respir Dis. 2018 Jan-Dec;12:1753465818754778
pubmed: 29411700
J Am Acad Dermatol. 2020 Nov;83(5):e361-e362
pubmed: 32593636
Hepatobiliary Pancreat Dis Int. 2019 Aug;18(4):307-312
pubmed: 31279679
Disaster Med Public Health Prep. 2020 Feb 05;:1-8
pubmed: 32019620
J Med Internet Res. 2017 May 17;19(5):e172
pubmed: 28526671
Surg Endosc. 2020 Jun;34(6):2541-2550
pubmed: 31399950
Transplantation. 1996 Jul 15;62(1):62-5
pubmed: 8693547
Am J Transplant. 2010 May;10(5):1276-83
pubmed: 20353467
Am J Transplant. 2018 Jan;18 Suppl 1:172-253
pubmed: 29292603
J Vasc Interv Radiol. 2014 Sep;25(9):1406-12
pubmed: 24854391
Eur Respir J. 2016 Sep;48(3):648-63
pubmed: 27390283
World J Transplant. 2020 Jan 18;10(1):15-28
pubmed: 32110511
Telemed J E Health. 2020 Aug;26(8):1066-1070
pubmed: 31804895
J Allergy Clin Immunol Pract. 2020 Jun;8(6):1908-1918
pubmed: 32084596
J Med Internet Res. 2020 Dec 11;22(12):e22703
pubmed: 33259324
World J Surg. 2020 Oct;44(10):3470-3477
pubmed: 32488663
J Surg Res. 2019 Jul;239:52-59
pubmed: 30802705
J Hepatol. 2012 Sep;57(3):675-88
pubmed: 22609307
Transplantation. 2008 Jun 27;85(12):1726-32
pubmed: 18580463

Auteurs

Min Tian (M)

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.

Bo Wang (B)

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.

Zhao Xue (Z)

National Local Joint Engineering Research Center for Precision Surgery & Regenerative Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.

Dinghui Dong (D)

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.

Xuemin Liu (X)

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.

Rongqian Wu (R)

National Local Joint Engineering Research Center for Precision Surgery & Regenerative Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.

Liang Yu (L)

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.

Junxi Xiang (J)

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.

Xiaogang Zhang (X)

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.

Xufeng Zhang (X)

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.

Yi Lv (Y)

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.

Classifications MeSH